Literature DB >> 11171802

Angiotensin II type 1 receptor blockers.

M Burnier1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171802     DOI: 10.1161/01.cir.103.6.904

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  97 in total

1.  Pharmacokinetic-pharmacodynamic model of fimasartan applied to predict the influence of a high fat diet on its blood pressure-lowering effect in healthy subjects.

Authors:  Jongtae Lee; Seunghoon Han; Sangil Jeon; Taegon Hong; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 2.  Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.

Authors:  Niels Holmark Andersen; Carl Erik Mogensen
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

3.  Functional role of sodium glucose transporter in high glucose-mediated angiotensin type 1 receptor downregulation in human proximal tubule cells.

Authors:  Rekha Yesudas; Russell Snyder; Thomas Abbruscato; Thomas Thekkumkara
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

Review 4.  Combination therapy of renin-angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis.

Authors:  Z Lu; Y Chen; L Li; G Wang; H Xue; W Tang
Journal:  J Hum Hypertens       Date:  2016-01-07       Impact factor: 3.012

5.  Angiotensin II receptor blockers.

Authors:  Amy Barreras; Cheryle Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

Review 6.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

7.  Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Authors:  M Hropot; K H Langer; Gabriele Wiemer; H Grötsch; W Linz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

8.  The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation.

Authors:  Ivana Domazet; Stéphane S Martin; Brian J Holleran; Marie-Eve Morin; Patrick Lacasse; Pierre Lavigne; Emanuel Escher; Richard Leduc; Gaétan Guillemette
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

Review 9.  Thick Ascending Limb Sodium Transport in the Pathogenesis of Hypertension.

Authors:  Agustin Gonzalez-Vicente; Fara Saez; Casandra M Monzon; Jessica Asirwatham; Jeffrey L Garvin
Journal:  Physiol Rev       Date:  2019-01-01       Impact factor: 37.312

10.  Recent clinical trials with omapatrilat: new developments.

Authors:  Anne Zanchi; Marc Maillard; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.